TALEN® enables gene editing
at industrial scale
Gene editing will completely reshape molecular medicine within five years. Our flagship TALEN® technology provides us with the ability to rethink how we treat diseases altogether. Cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more. It is the next transformative step in medicine.
that can work for the largest number of patients
Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapies product candidates that are designed to work for the largest number of patients. It’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in designing therapies for many other diseases.
Strong intellectual property,
global strategic partnerships.
17 years of innovation. 111 patent families. 75 granted patents and 443 applications. Global strategic partnerships with Pfizer, Servier, and leading Universities all over the world.